Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tania Stallons"'
Publikováno v:
Mol Cancer Ther
Somatostatin analogues have been examined as a treatment for somatostatin receptor overexpressing tumors for years; specifically, octreotate (TATE) and octreotide (TOC). Several versions of these analogues coupled to beta or gamma nuclides are curren
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals.
Background: Targeted α particle therapy using long-lived in vivo α particle generators is cytotoxic to target tissues. However, the redistribution of released radioactive daughters through the circ...
Autor:
Jostein Dahle, Amal Saidi, Tania Stallons, Helen Heyerdahl, Ada Repetto-Llamazares, Julien Torgue
Publikováno v:
Cancer Research. 82:5432-5432
Introduction: CD37 has shown promise as a new therapeutic target for B-cell malignancies. CD37 is highly and selectively expressed on the surface of mature B lymphocytes and B-cell malignancies. Alpha-emitting radionuclides have demonstrated potentia
Autor:
Astri Maaland, Jostein Dahle, Arne Kolstad, Tania Stallons, Amal Saidi, Julien Torgue, Helen Heyerdahl
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 3, p e0230526 (2020)
PLoS ONE, Vol 15, Iss 3, p e0230526 (2020)
Relapse of chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma after standard of care treatment is common and new therapies are needed. The targeted alpha therapy with 212Pb-NNV003 presented in this study combines cytotoxic α-particles from 2
Autor:
Farah Shanoon, Tania Stallons, Ebrahim S. Delpassand, Ali Muzammil, Luke Bolek, Michael Ghaly, Bin He, Eric C. Frey, Amal Saidi, Izabela Tworowska, Julien Torgue, George Sgouros
Publikováno v:
Journal of Medical Imaging and Radiation Sciences. 50:S105-S106
Autor:
Julien Torgue, Amal Saidi, Garry E. Kiefer, Izabela Tworowska, Tania Stallons, George Sgouros, Ebrahim S. Delpassand, F. Rojas-Quijano, Mickel Ghaly, Eric C. Frey, Paul Jurek
Publikováno v:
Nuclear Medicine and Biology. :S19-S20
Autor:
Garry E. Kiefer, Izabela Tworowska, Amal Saidi, Julien Torgue, Paul Jurek, Ebrahim S. Delpassand, Tania Stallons, Federico Rojas-Quijano, Nilesh K. Wagh
Publikováno v:
Cancer Research. 77:LB-259
Objective: The peptide receptor radionuclide therapy (PPRT) for somatostatin receptor positive (SSTR) neuroendocrine tumors (NETs) has emerged more than 15 years ago. The beta-emitter-PRRT has shown to induce objective response in 30-45% of metastati